Consolidated Water Co. Ltd. (CWCO)
The 3 Most Undervalued Water Stocks to Buy in July 2024
Many value investors own one or more undervalued utility stock, including water stocks. Typically, these stocks are low on growth, pay steady dividends and carry a price-to-earnings (P/E) ratio in the single digits.
Consolidated Water (CWCO) Laps the Stock Market: Here's Why
Consolidated Water (CWCO) closed the most recent trading day at $25.36, moving +1.2% from the previous trading session.
Consolidated Water (CWCO) Rises Higher Than Market: Key Facts
Consolidated Water (CWCO) concluded the recent trading session at $25.21, signifying a +0.24% move from its prior day's close.
Why the Market Dipped But Consolidated Water (CWCO) Gained Today
The latest trading day saw Consolidated Water (CWCO) settling at $25, representing a +0.68% change from its previous close.
Consolidated Water (CWCO) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Consolidated Water (CWCO) settling at $25, representing a -0.75% change from its previous close.
Consolidated Water (CWCO) Rides on Usage of Latest Technology
Consolidated Water (CWCO) uses the most advanced technology to serve customers more efficiently. It aims to expand operations through strategic alliances and acquisitions.
Consolidated Water: Strong Balance Sheet And Promising Development
Consolidated Water achieved a 91.5% YoY increase in revenue and reached all-time high margins and profitability in FY23. The company has a solid balance sheet with net debt of $-43.7m and potential for new strategic acquisitions and a share buyback plan. The company's business model faces risks, including the renewal of its water sales license in the retail segment, but its financial strength and growth trends justify a buy rating.
Consolidated Water urges shareholders to vote for re-election of key directors
Consolidated Water Co has expressed strong disagreement with the recommendations from Institutional Shareholder Services (ISS) and Glass Lewis to withhold votes for the re-election of three of its board members. The company is urging shareholders to vote in favour of the re-election of Linda Beidler-D'Aguilar, Brian Butler, and Leonard Sokolow at the upcoming annual general meeting on May 28.
Consolidated Water urges shareholders to vote for re-election of key directors
Consolidated Water Co has expressed strong disagreement with the recommendations from Institutional Shareholder Services (ISS) and Glass Lewis to withhold votes for the re-election of three of its board members. The company is urging shareholders to vote in favour of the re-election of Linda Beidler-D’Aguilar, Brian Butler, and Leonard Sokolow at the upcoming annual general meeting on May 28. Consolidated Water noted that Beidler-D’Aguilar, who has attended 69% of board and committee meetings in 2023, missed the 75% threshold due to a prior commitment. However, she has pledged to meet the attendance requirement in 2024 and has attended all meetings to date, the group added, emphasising her “35 years of experience as an attorney; her legal, business and financial knowledge acquired during that period; and her knowledge of, and business contacts in, the Caribbean”. Butler, who chairs the Nominations and Corporate Governance Committee, has been recommended against by Glass Lewis due to concerns over board refreshment and gender diversity. Consolidated Water replied: "The company, the board and the NCG are very satisfied with the composition of the board and would be hesitant to make a change solely based upon age, tenure or diversity consideration." “The board believes that it is important that Mr. Sokolow be re-elected because of his experience as a director and principal executive officer; his legal, accounting, auditing and consulting background; and his qualifications to serve as the company’s ‘audit committee financial expert’”, said Consolidated Water. “We urge stockholders to follow the board’s recommendation and vote ‘FOR’ all the proposals in the proxy statement, including the re-election of Ms. Beidler-D’Aguilar, Mr. Butler and Mr. Sokolow,” said the company in a statement. Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results at the 15th Annual T-Cell Lymphoma Forum (TCLF) to be held in California from June 6 to 8. The Phase 1b study of PTX-100, which targeted patients with relapsed and refractory T-cell lymphomas (r/r TCLs), has met its primary goals of demonstrating safety and determining both pharmacokinetics – how the drug is absorbed, distributed, metabolised and excreted in the body – and pharmacodynamics, or the effects of the drug on the body. Additionally, the study has shown promising preliminary efficacy in r/r TCL patients, surpassing the typical results expected from standard treatments, with an overall response rate of 45%. This means that five out of 11 evaluable TCL patients responded positively to the treatment. T-cell lymphomas (TCLs) are a type of non-Hodgkin lymphoma that originates from T-cells, a kind of white blood cell. TCLs are considered an orphan disease, which means they are rare, with around 30,000 cases. There is a significant need for more effective treatments for TCLs, especially for those with relapsed and refractory disease. Accordingly, PTX-100 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA), a status given to drugs intended for the treatment of rare diseases. The 15th annual T-Cell Lymphoma Forum (TCLF) is a specialised conference focusing on the latest and most significant advancements in T-cell lymphomas, including new agents and treatment approaches. It brings together clinicians, scientists and industry professionals dedicated to TCLs. The PTX-100 study results will be presented in a plenary address by the study's Principal Investigator, Professor H. Miles Prince, AM, a distinguished haematologist and globally recognized expert in TCLs. Prescient Therapeutics managing director and CEO Steven Yatomi-Clarke said: “The TCLF is an esteemed platform for sharing the latest research and developments in the field of TCLs. “To be invited to present our data in a coveted slot to world leaders in the field of TCLs showcases the relevance and potential of PTX-100 in this area of unmet need. “It also highlights the momentum and standing that Prescient has in this specialised community of TCL clinicians and drug developers, having previously presented at the American Society of Hematology 65th Annual Meeting and the 5th World Congress of Cutaneous Lymphomas. “Prescient is committed to advancing into a Phase 2 trial in r/r TCL, with the study aiming to commence in Q3 2024. The company believes this will be a big catalyst for Prescient, potentially offering a new beacon of hope for patients with limited treatment options.”
Consolidated Water Co. Ltd. (CWCO) Q1 2024 Earnings Call Transcript
Consolidated Water Co. Ltd. (NASDAQ:CWCO ) Q1 2024 Earnings Conference Call May 16, 2024 11:00 AM ET Company Participants Frederick McTaggart - CEO David Sasnett - CFO Conference Call Participants David Thomas - BoA Matthew Schwarz - Maze Investments Brandon Rogers - ROTH Capital John Bair - Ascend Wealth Advisors Operator Good morning, thank you for joining us today to discuss Consolidated Water Company's First Quarter 2024 Results.
Consolidated Water (CWCO) Q1 Earnings & Sales Beat Estimates
Consolidated Water's (CWCO) first-quarter 2024 earnings and revenues increase year over year. General and administrative expenses decrease during the same period.
